New study supported by DFE Pharma and Granutools reveals deeper understanding of factors impacting formulation flow

Goch, Germany (10^th Aug 2021) – DFE Pharma, a global leader in pharmaceutical excipient solutions, is continuously supporting relevant scientific research and innovations in its field.

With the recent publication of a new study demonstrating the impact of powder properties on the rheological behavior of excipients, DFE Pharma together with Belgium-based Granutools, gained a deeper mechanistic understanding of factors impacting the flow of a formulation into tableting dies. Though there are many flow characterization techniques, so far only very few have shown to mimic the die filling process successfully.

“One of the challenges in mimicking the die filling process is the impact of rheological powder behavior as a result of differences in flow field in the feeding frame”, comments DFE Pharma’s Pauline Janssen, one of the principal researchers.

“In this study, we investigated the rheological behavior for a wide range of excipients with a wide range of material properties. We introduced a new parameter for rheological behavior, which is a measure for the change in dynamic cohesive index upon changes in flow field”, Janssen adds.

The researchers identified particle size distribution as a main contributing factor to the rheological behavior of powders. The presence of fines between larger particles turned out to reduce the rheological index, which the authors explain by improved particle separation at more dynamic flow fields. This study also revealed that obtained insights on rheological behavior can be used to optimize agitator settings in a tableting machine.

For more information, visit https://www.mdpi.com/1999-4923/13/8/1198 

-END-

About DFE Pharma

DFE Pharma is a global leader in pharmaceutical excipient solutions. We strive to develop, produce and supply the highest quality functional excipients for use in the pharmaceutical, biopharmaceutical and nutraceutical industries for respiratory, oral solid dose (OSD), ophthalmic and parenteral formulations.

Our excipients play an essential role as fillers, binders, disintegrants, and in stabilising active ingredients for release in a predictable and effective manner into the patient’s system. With over a century of experience and over 400+ people worldwide in over 100 countries serving over 5000 customers, DFE Pharma is committed to supporting (bio)pharmaceutical and nutraceutical companies in their journey to improve patients’ lives. We are driven by our purpose your medicines, our solutions. Moving to a healthier world.

Learn more at www.dfepharma.com or follow us on LinkedIn 

--------------------------

For media enquiries 

Amanda Leweson - Discovery PR, on behalf of DFE Pharma 

Email: amanda@discovery-pr.com  

Mobile: + 44 (0) 7852 153 791  

Office:   +44 (0) 1606 889 194